Patients whose NSCLC was tested for PD-L1 were more likely to have NSCLC initially diagnosed at stage IV (83% vs. 70% of those not tested; p < 0.001), of nonsquamous histology (76% vs. 68%; p < 0.001), and tested for EGFR mutation and ALK rearrangement (87% vs. 56%; p < 0.001; Table 1). Here, CD274 is linked to non-small cell lung carcinoma.